Melatonin receptor (MT receptor) (MT receptor)

Melatonin receptors, specifically the MT1 (MTNR1A) and MT2 (MTNR1B) subtypes, are high-affinity G protein-coupled receptors that mediate the biological effects of the hormone melatonin [1, 2]. These receptors are primarily located in the suprachiasmatic nucleus of the hypothalamus, where they play a central role in regulating the body's internal clock and sleep-wake cycles [3, 4]. MT1 activation is associated with sleep induction, while MT2 is primarily involved in the synchronization (phase-shifting) of the circadian rhythm [1]. Beyond the central nervous system, these receptors are expressed in various peripheral tissues, contributing to functions such as immune modulation, antioxidant defense, and cardiovascular regulation [2, 4]. Dysregulation of melatonin receptor pathways is linked to sleep disorders, depression, and neurodegenerative conditions like Alzheimer's disease [3]. Therapeutic agents like ramelteon and agomelatine target these receptors to treat insomnia and mood disorders by mimicking the endogenous action of melatonin [1, 3]. Understanding these pathways is crucial for developing chronobiological treatments that align physiological processes with environmental light-dark cycles.

Other names

Melatonin receptor type 1AMelatonin receptor type 1BMT1 receptorMT2 receptorMTNR1AMTNR1BMel1aMel1b

Drugs targeting melatonin receptor pathways primarily act as agonists at the MT1 and MT2 receptors. MT1 activation inhibits adenylyl cyclase activity via Gi proteins, leading to a decrease in cAMP levels and the inhibition of neuronal firing in the suprachiasmatic nucleus (SCN) [1, 2]. MT2 activation also inhibits adenylyl cyclase and is involved in the phase-shifting of circadian rhythms through the phosphoinositide pathway [1, 4]. These actions collectively mimic the endogenous effects of melatonin to regulate sleep and circadian timing.